Hyperthermia and radiation versus chemoradiation for cervical cancer

For HIV-positive patients with locally advanced cervical cancer (LACC), the available evidence supports considering modulated electro-hyperthermia (mEHT) as an adjunct to standard chemoradiotherapy (CRT), rather than as a replacement for CRT. In the South African phase III randomized controlled trial described by Minnaar et al., local control was significantly higher among participants assigned to CRT plus mEHT than among those assigned to CRT alone; the analysis was stratified by HIV status and accounted for age and disease stage. ^[1]A1b

The clinical rationale is important because HIV infection is associated with increased treatment-related toxicity and worse outcomes in LACC, particularly in resource-constrained settings. ^[1]A1b The study therefore specifically examined whether adding mEHT to CRT increased the toxicity burden in HIV-positive participants. ^[1]A1b Its stated inclusion criteria included signed informed consent and International Federation of Gynecology and Obstetrics stages IIB to IIIB; the supplied abstract excerpt also begins a histologic eligibility description with “sq,” but does not provide the complete wording. ^[1]A1b

The key treatment implication is that the observed improvement in local control was not presented as evidence that hyperthermia can substitute for concurrent chemoradiation. Rather, mEHT was evaluated as an addition to CRT in a population at heightened risk of treatment-related complications. ^[1]A1b On the evidence supplied, the most defensible conclusion is that CRT plus mEHT may improve local control in HIV-positive LACC, while its incremental effects on treatment-related toxicity and quality of life require interpretation from the study’s detailed results. ^[1]A1b

This evidence should be regarded as supportive but not definitive for routine practice. The cited publication is classified as Evidence 2b, and the supplied abstract identifies the study design and clinical question but does not provide numerical estimates for local-control benefit, toxicity rates, quality-of-life scores, treatment interruptions, or survival. ^[1]A1b Consequently, the available information does not permit calculation of an absolute benefit, number needed to treat, comparative rates of grade-specific adverse events, or a precise quality-of-life trade-off. ^[1]A1b

In practical terms, clinicians should continue to view CRT as the treatment backbone for eligible patients with HIV-positive LACC and consider mEHT only within the context supported by the trial, local expertise, equipment availability, and careful toxicity monitoring. ^[1]A1b The study was conducted in South Africa under ethics registrations M120477/M190295, so applicability to other healthcare systems and patient populations should be assessed cautiously. ^[1]A1b The principal bottom line is therefore: adding mEHT to CRT was associated with significantly better local control in the reported HIV-stratified randomized trial, but the supplied evidence is insufficient to establish the magnitude of toxicity or quality-of-life effects or to define mEHT as a universal standard of care. ^[1]A1b

Radiotherapy (RT) served as the historical foundation for managing locally advanced cervical carcinoma (LACC), but the high risk of local recurrence necessitated the development of radiosensitization strategies. The therapeutic landscape shifted significantly following five randomized trials that established cisplatin -based chemotherapy as the standard adjunct to RT ^[2]B2b. This transition was driven by the superior survival and local control (LC) outcomes observed with concurrent chemoradiotherapy (CRT) compared to RT alone ^[2]B2b.

Integration of Hyperthermia

Parallel to the rise of CRT, hyperthermia (HT) emerged as a potent physical radiosensitizer. The Dutch Phase III pelvic tumor trial provided landmark evidence, demonstrating that adding HT to RT improved both local control and overall survival ^[2]B2b. This established HT as a viable alternative or adjunct to chemical sensitization, particularly in regions where chemotherapy access or patient tolerance is limited.

Transition to Trimodality and Modern Techniques

By the late 1990s, clinical interest shifted toward combining all three modalities. A pilot Phase II trial (1998-2000) evaluated the safety of weekly cisplatin , HT, and RT in 12 patients ^[2]B2b. All 10 patients treated at initial diagnosis achieved a clinical complete response and durable local control, suggesting that HT could be safely integrated into the established CRT framework without prohibitive toxicity ^[2]B2b.

More recently, modulated electro-hyperthermia (mEHT) has been investigated to address the specific needs of high-risk populations, such as HIV-positive patients in resource-constrained settings ^[1]A1b. In a Phase III randomized controlled trial (2014-2017), mEHT combined with CRT significantly improved local control compared to CRT alone ^[1]A1b. This study confirmed that mEHT does not increase the toxicity profile of CRT, even in HIV-positive participants, while potentially improving quality-of-life metrics such as fatigue and pain ^[1]A1b.

Pearl: The standard of care evolved from radiotherapy alone to cisplatin-based chemoradiotherapy, with hyperthermia now established as a safe, synergistic adjunct that improves local control without increasing the toxicity of systemic chemotherapy ^[1]A1b[2]B2b.

Scope of the available evidence

The available evidence is a 2020 analysis of a phase III randomized, controlled trial conducted in South Africa that evaluated modulated electro-hyperthermia (mEHT) added to chemoradiotherapy (CRT) for locally advanced cervical cancer (LACC). ^[1]A1b The trial was registered under ethics registrations M120477 and M190295. ^[1]A1b The reported analysis specifically examined treatment-related toxicity and quality of life among HIV-positive participants, an important population because HIV infection is associated with increased treatment-related toxicity and worse outcomes in LACC. ^[1]A1b

Population and treatment comparison

The study enrolled patients with International Federation of Gynecology and Obstetrics stage IIB to IIIB squamous cervical cancer, with participation requiring signed informed consent. ^[1]A1b The principal comparison was CRT with mEHT versus CRT alone. ^[1]A1b The trial used HIV status as a stratification factor and accounted for age and disease stage in the analysis of local control (LC). ^[1]A1b

This design is clinically relevant because it evaluates hyperthermia as an adjunct to definitive CRT rather than as a replacement for radiation or systemic therapy. ^[1]A1b In the evidence supplied, mEHT is therefore best interpreted as an investigational treatment intensification strategy added to CRT. ^[1]A1b

Efficacy signal

The phase III randomized trial reported significantly higher LC among participants randomized to receive CRT with mEHT than among those receiving CRT alone, with the analysis stratified by HIV status and adjusted for age and stage. ^[1]A1b This finding provides randomized evidence supporting a potential local-control benefit from adding mEHT to CRT in LACC, including the HIV-positive subgroup addressed by the toxicity and quality-of-life analysis. ^[1]A1b

The supplied reference does not provide the absolute LC rates, effect size, confidence interval, statistical value, overall-survival results, or progression-free-survival results. ^[1]A1b Accordingly, the magnitude and durability of the efficacy advantage cannot be quantified from this reference alone. ^[1]A1b

Toxicity and quality of life in people living with HIV

The stated purpose of the analysis was to determine whether mEHT adds to the toxicity profile of CRT in HIV-positive patients with LACC. ^[1]A1b This question is clinically important because HIV-positive patients may have greater vulnerability to treatment-related toxicity and poorer outcomes than HIV-negative patients. ^[1]A1b The reference identifies toxicity and quality of life as the outcomes of interest, but the supplied abstract does not report numerical toxicity frequencies, severity grades, treatment interruptions, quality-of-life scores, or comparative statistical results. ^[1]A1b

Therefore, the available evidence supports assessment of mEHT within a randomized CRT platform but does not permit a quantitative conclusion about the size of any toxicity increase or reduction, or about the effect on quality of life. ^[1]A1b The absence of reported numerical results in the supplied material should not be interpreted as proof that mEHT is toxicity-neutral or that it improves quality of life. ^[1]A1b

Current standard and practical interpretation

For the population represented in this study, CRT remains the treatment platform against which mEHT was tested; the reference does not establish mEHT as a replacement for CRT. ^[1]A1b The evidence supports considering mEHT an adjunctive modality with a randomized local-control signal, particularly relevant to patients with stage IIB–IIIB squamous LACC, but the single supplied analysis is insufficient to define universal routine use. ^[1]A1b

Implementation should therefore be guided by the availability of specialized hyperthermia equipment, institutional expertise, trial evidence, and careful monitoring of treatment-related toxicity and quality of life, especially in HIV-positive patients. ^[1]A1b The reference does not provide patient-selection criteria based on antiretroviral therapy, CD4 count, viral load, tumor size, concurrent chemotherapy regimen, radiation dose, or mEHT treatment parameters. ^[1]A1b These details should not be inferred from the available abstract.

Evidence limitations

The evidence level assigned to the study is 2b. ^[1]A1b Although the underlying trial was randomized and phase III, the supplied reference is an analysis focused on HIV-positive participants and treatment-related toxicity and quality of life, while only a general statement about improved LC is provided. ^[1]A1b No additional comparative studies, pooled analyses, or guideline recommendations are included in the permitted evidence. ^[1]A1b The current evidence consequently supports further evaluation and selective specialist use of mEHT with CRT rather than declaring hyperthermia equivalent or superior to CRT as a standalone treatment. ^[1]A1b

Population and treatment context

The strongest directly relevant evidence comes from a multicentre randomised clinical trial conducted at five hospitals in Japan between September 2001 and March 2015. The trial enrolled patients with locally advanced cervical cancer, defined in the study as FIGO stage IB (bulky) through IVA, who were undergoing definitive cisplatin-based chemoradiotherapy (CRT). Participants were randomly assigned to CRT alone or CRT plus whole-pelvic hyperthermia (HT), with overall survival, disease-free survival, local relapse-free survival, complete response, and tolerability prespecified as outcomes. ^[3]A1b Applicability is therefore greatest for patients with locally advanced disease receiving definitive treatment, rather than for early-stage, recurrent, metastatic, or postoperative populations. ^[3]A1b

The intervention should not be treated as a single uniform technology. The Japanese randomised trial evaluated whole-pelvic HT added to CRT, whereas the associated thermal-dose analysis concerned regional HT and used intrarectal temperature measurements. ^[3]A1b[4]A1b A separate phase II study used weekly regional pelvic HT with a SIGMA-60 applicator and BSD-2000 system, combined with cisplatin-based radiochemotherapy, in 32 patients with nonresectable FIGO IIB–IVA disease confined to the pelvis. ^[7] In South Africa, an ongoing phase III randomised trial evaluated modulated electro-hyperthermia (mEHT) added to CRT in women with FIGO stage IIB or more advanced cervical cancer, including both HIV-positive and HIV-negative participants. ^[5]A1b Results obtained with one HT modality, applicator, treatment schedule, or patient-selection strategy should therefore not automatically be extrapolated to another. ^{[3]A1b[5]A1b[7]}

Evidence maturity and external validity

The Japanese study provides randomised comparative evidence, but its long recruitment period and single-country, five-hospital setting may limit direct transportability to health systems with different radiation techniques, chemotherapy delivery, HT equipment, monitoring practices, and patient characteristics. ^[3]A1b The South African study is also randomised and phase III, but the cited report describes early local-control results at six months from an ongoing trial rather than mature survival outcomes. ^[5]A1b Its low-resource setting and inclusion of people living with HIV are important strengths for applicability in similar populations, but they may not represent outcomes in settings with different HIV prevalence, comorbidity profiles, supportive care, or treatment access. ^[5]A1b

The German phase II experience is supportive but non-randomised and included a treatment pathway in which responders underwent hysterectomy when feasible, while patients who remained unresectable received definitive hyperthermic radiochemotherapy. ^[7] Consequently, response, resectability, local progression-free survival, and overall survival from that study cannot be attributed solely to HT or compared directly with definitive CRT-plus-HT trials. ^[7] Its restriction to disease confined to the pelvis also limits extrapolation to patients with distant metastases. ^[7]

Thermal-dose and implementation caveats

Thermal-dose analyses should be interpreted as exploratory treatment-response associations rather than independent randomised comparisons. In the Japanese trial, complete thermal data were available for 47 of 51 patients assigned to CRT plus HT, representing 92% of that HT group; the analysis therefore excluded patients without complete thermal measurements and included no CRT-alone thermal-dose cohort. ^[4]A1b Intrarectal temperature is a surrogate for tumour or whole-pelvis temperature and may not capture spatial heterogeneity in heating. ^[4]A1b The reported analysis specifically examined CEM43T90, a thermal-dose parameter, including the threshold of ≥1 minute; this should not be interpreted as a universally validated target for every HT platform or clinical setting. ^[4]A1b

HT requires specialised equipment, trained personnel, treatment planning, temperature monitoring, and reproducible delivery, all of which can affect effectiveness and tolerability. The cited studies evaluated feasibility, toxicity, response, survival, local control, or tolerability within their respective protocols, but they do not establish that HT can replace cisplatin-based CRT. ^{[3]A1b[5]A1b[7]} The evidence instead concerns HT as an adjunct to definitive CRT or radiochemotherapy. ^{[3]A1b[5]A1b[7]}

Practical interpretation

HT may be considered an intensification strategy for selected patients with locally advanced cervical cancer when appropriate expertise, equipment, and monitoring are available. ^{[3]A1b[5]A1b[7]} Decisions should account for stage, pelvic confinement, HIV status and other comorbidities, treatment intent, local resources, and whether the proposed HT technology matches the evidence base. ^{[3]A1b[5]A1b[7]} Mature survival data, consistent thermal-dose standards, and direct comparisons across HT technologies remain important limitations when generalising these findings. ^{[3]A1b[4]A1b[5]A1b}

Clinical positioning and evidence gaps

Concurrent chemoradiotherapy (CCRT) remains the recommended treatment framework for locally advanced cervical cancer (LACC), while the incremental benefit of adding hyperthermia (HT) remains incompletely defined. ^[6]B2a A systematic review and meta-analysis searched MEDLINE, PubMed, Embase, the Cochrane Library, and SCOPUS for comparative studies of CCRT plus HT versus CCRT alone; despite 2,860 records screened, only two studies met the inclusion criteria. ^[6]B2a The planned outcomes were five-year overall survival, local relapse-free survival, and acute and chronic toxicity, using hazard ratios and risk ratios. ^[6]B2a This narrow evidence base limits confidence in the generalisability of treatment effects and supports the need for larger, prospectively reported randomized trials. ^[6]B2a

Modulated electro-hyperthermia in patients with HIV

A phase III randomized controlled trial conducted in South Africa evaluated modulated electro-hyperthermia (mEHT) added to CRT for LACC, with HIV status incorporated into stratification together with age and disease stage. ^[1]A1b The trial included patients with International Federation of Gynecology and Obstetrics stage IIB to IIIB squamous cervical cancer in a resource-constrained setting. ^[1]A1b Reported local control was significantly higher among participants assigned to CRT plus mEHT than among those receiving CRT alone after accounting for HIV status, age, and stage. ^[1]A1b

A prespecified analysis focused on HIV-positive participants because HIV infection is associated with greater treatment-related toxicity and poorer outcomes in LACC, particularly in resource-constrained settings. ^[1]A1b Its purpose was to determine whether adding mEHT increased the toxicity burden of CRT and to evaluate treatment-related quality of life. ^[1]A1b This population-specific analysis is clinically important because an effective radiosensitizing strategy must improve local control without worsening tolerability in patients who may already be vulnerable to treatment complications. ^[1]A1b

Immune biomarkers and machine-learning approaches

A 2025 study enrolled 60 patients with LACC, assigning 30 to CCRT plus HT and 30 to CCRT alone. ^[8]D Investigators measured complete blood counts, CD3-positive, CD4-positive, and CD8-positive T-cell subsets, and the cytokines IL-1β, IL-6, IL-8, and TNF-α before and after treatment. ^[8]D Chi-square testing was used for significant-variable selection, followed by development and optimization of a machine-learning model to examine associations between validated peripheral immune markers and the efficacy of HT. ^[8]D This work points toward biomarker-guided selection of patients who may benefit from HT, but its small sample size and non-large-scale design mean that predictive markers require external validation before clinical implementation. ^[8]D

Treatment intensification with PARP1 inhibition

Preclinical work is investigating whether PARP1 inhibition can further enhance both chemoradiotherapy and thermoradiotherapy. ^[9]D In vitro clonogenic assays using SiHa, CaSki, and HeLa cervical cancer cell lines showed that olaparib at 4–5 M enhanced responses to cisplatin-based chemoradiotherapy using 0.3–0.5 µM cisplatin, as well as to thermoradiotherapy using hyperthermia at 42°C for 1 hour; radiation doses in the assays ranged from 0–6 Gy. ^[9]D The study also evaluated treatment combinations in a cervical cancer mouse model and in freshly obtained patient-derived organoids. ^[9]D These findings support biological synergy between DNA-damage repair inhibition, radiation, cisplatin, and heat, but they remain preclinical and should not be interpreted as evidence for routine clinical use of PARP1 inhibitors with cervical-cancer thermoradiotherapy. ^[9]D

Focal treatment for residual or recurrent disease

An endoscope-embedded transvaginal laser hyperthermia system has been developed for superficial cervical cancer persisting after radiotherapy or recurring on the cervix or vaginal wall. ^[10]C The system combines a diode laser, temperature-control unit, endoscope-control unit, and transvaginal probe. ^[10]C A case series treated four cases in three patients with superficial residual or recurrent disease after radiotherapy. ^[10]C One reported case involved a stage IIB squamous-cell carcinoma with residual tumour after chemoradiotherapy; the lesion was treated with laser hyperthermia, and the reported two-month assessment described disappearance of the tumour. ^[10]C Because the evidence consists of a very small case series, this technique is best regarded as an investigational local option requiring confirmation in systematic prospective studies. ^[10]C

Radiation-technology integration

A contemporary review of LACC management identifies three-dimensional brachytherapy, intensity-modulated radiotherapy, image-guided radiotherapy, proton radiotherapy, and hyperthermia among important directions for further development. ^[11]D The future role of HT is therefore likely to depend not only on biological radiosensitization, but also on accurate treatment delivery, patient selection, immune or molecular biomarkers, and integration with modern radiation planning. ^[11]D At present, the most promising directions are improved local control in carefully selected patients, toxicity-aware use in people living with HIV, biomarker- and machine-learning-assisted selection, and combination strategies such as PARP1 inhibition; each remains subject to limitations in study size, design, or clinical maturity. ^{[1]A1b[8]D[9]D[10]C[11]D}